A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Adding PARP inhibitor niraparib to standard prostate cancer treatment delays disease progression in men with certain DNA ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Men with advanced prostate cancer undergoing local therapies such as radiation therapy or radical prostatectomy experience significantly more gastrointestinal and sexual issues, along with problems ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about managing side effects following prostate cancer treatment. While treatment ...

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

There is no single, diagnostic test. Doctors make a diagnosis based on various measures. This can include a prostate-specific ...

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

The six biggest myths about prostate cancer - NHS data noted a significant 25 per cent surge in prostate cancer cases between ...

Sunak is an ambassador for Prostate Cancer Research, which is publishing a report on the costs and benefits of a targeted ...